Stronger immune restraint restores protective killing by ending unproductive cell contacts
In aged-donor immune–epithelial cultures, bounded stimulation of programmed cell death protein 1 (PD-1) would restore antiviral and malignant-target killing before repair is complete. The mechanism is rejected if either killing function fails to improve or the benefit persists under single-target confinement.
Omega Point 1.2
Stage of verification
- Hypothesis published2026-09-21
- Indirect evidenceAssessed at 4 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Biological function
Kind of knowledge gap
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.
Receptor or channel
PD-1
An immune checkpoint receptor that mediates restraint of cytotoxic-cell encounters
Where this hypothesis actsOlder-adult cytotoxic cells after verified pathogen control, before tissue repair is complete
Hypotheses on this target 1
Lower level
Higher level
Blockade
Agonism1
Desensitisation
Function restoration
Function preservation
What is proposed
Agonism
Increase PD-1-mediated restraint within a bounded range
With whatAntibody or binding reagent
HowReversible PD-1 agonism using Fc-silent reagents with demonstrated agonism and measured receptor engagement
Possible result
Possible shorter bystander contacts, improved antiviral and abnormal-cell killing, and less uninfected-cell injury
From the recordCompare reversible PD-1 agonism, blockade, and controls at matched repair stages.
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
An aging immune system may struggle to find and destroy dangerous cells while damaged tissue is still healing. The unexpected move is to strengthen an immune brake: the pipeline proposes that this could release killing cells from harmless encounters and let them reach more infected and cancerous cells. That is a generated hypothesis, not a measured recovery of immune protection.
- Repairing, uninfected cells are proposed to hold killing cells in prolonged contacts that do not kill a dangerous target.
- These persistent contacts are proposed to keep killing cells from reaching additional infected and cancerous cells.
- Stronger PD-1 signaling within an unspecified bounded range is proposed to switch weak encounters from persistent attachment to contact termination.
- Strong encounters with infected or cancerous cells are proposed to retain their ability to end in killing.
- Freed killing cells are predicted to destroy more distinct dangerous targets per cell per hour while causing less injury to uninfected cells, even before repair is complete.
A security worker can miss real trouble by spending too long checking harmless visitors. A rule that ends those checks sooner could increase the number of real problems handled even if each check becomes less intense.
Where the picture breaks: Immune cells do not recognize harmless visitors with certainty. The proposal must establish that stronger restraint ends unproductive contacts without also preventing the killing of dangerous targets.
- Master questionstep 01 of 04
Restoring immune protection in older people means recovering both innate immunity, the body's broadly responsive defenses, and adaptive immunity, defenses directed at particular threats. Recovery must last while preserving immunological memory, protection retained from previous encounters; self-tolerance, avoidance of attacks on healthy tissue; and control of latent infections, infections that persist without continuously causing active disease.
Rests on: The goal defines success as durable recovery within healthy young-adult ranges while retaining these existing protections. It does not report that this recovery has been achieved.
Stated in the chain - Goal pillarstep 02 of 04
Immune defenses must recover after repeated demands and resist interruptions in surveillance, the ongoing detection and removal of dangerous cells.
Rests on: The master goal requires durable protection, which supplies the basis for examining recovery after repeated demands and continuity of protection.
Stated in the chain - Gap questionstep 03 of 04
The timing of lifting immune restraint after an infection is controlled may determine whether protection returns or tissue injury worsens. The question considers whether early release damages healing tissue and delayed release makes suppression persist.
Rests on: The preceding stage identifies recovery and uninterrupted protection as requirements, but supplies no mechanism connecting them to the timing of restraint release.
LeapNeither the preceding text nor the supplied sources establishes the proposed timing relationship among verified infection control, tissue repair, restraint release, and persistent suppression.
- Hypothesisstep 04 of 04
Some older adults may lose protective killing because immune cells remain attached to uninfected cells undergoing repair. The proposal assigns PD-1 restraint a contact-ending role: stronger signaling would interrupt weak, harmless encounters while allowing encounters with infected or cancerous targets to finish in killing. Weakening that restraint is predicted to increase activity during each encounter while trapping killing cells among repairing cells.
Rests on: The gap question supplies the setting of controlled infection, ongoing repair, and impaired protection. It does not supply the proposed cause of prolonged harmless contacts or the proposed contact-ending function of PD-1.
LeapThe missing bridge is a basis for assigning surveillance failure to persistent contacts with repairing cells and assigning their termination to PD-1. The leap concerns that mechanistic bridge, not the fact that the endpoint is an untested proposal.
What is carried, and what is not. None of the eight supplied sources establishes the defining contact-release mechanism; one directly supports an inhibitory component: the 2021 JCI Insight study reports that PD-1-stimulating molecules reduced signaling-protein release and self-directed killing by T cells, a type of adaptive immune cell, in laboratory culture, but it does not establish contact termination or improved protective killing in older adults (S5). No supplied source establishes the proposed sequence from stronger restraint to restored antiviral and cancer-cell killing.S5
Where the reasoning is carried by something unstated · 2
- Gap question. Neither the preceding text nor the supplied sources establishes the proposed timing relationship among verified infection control, tissue repair, restraint release, and persistent suppression. Establish the missing link before relying on this step.
- Hypothesis. The missing bridge is a basis for assigning surveillance failure to persistent contacts with repairing cells and assigning their termination to PD-1. The leap concerns that mechanistic bridge, not the fact that the endpoint is an untested proposal. Establish the missing link before relying on this step.
How a result here could mislead · 3
- More targets killed per immune cell per hour could reflect easier-to-kill targets or altered killing-cell survival rather than release from harmless contacts. Less injury to uninfected cells could separately reflect general suppression of killing. What closes it: The proposed live imaging must distinguish contact duration, new encounters, and the chance of killing after an encounter. Counts must also account for surviving killing cells and available targets, and improved killing must occur for both infected and cancerous targets alongside reduced uninfected-cell injury.
- Loss of benefit under single-cell confinement could be credited to removing harmless contacts when confinement itself has changed baseline killing or the strength of PD-1 stimulation. What closes it: The confined and freely interacting conditions must have comparable targets, repair stages, treatment exposure, and measured engagement of PD-1. Baseline killing must leave room to detect improvement; otherwise disappearance of benefit is ambiguous.
- A change in protective killing could be attributed to contact release without separating the rival explanation: accumulated production activity for interleukin-10 (IL-10), an immune-suppressing signaling protein, may keep restraint elevated after injury subsides. Matching current repair stages does not necessarily match that accumulated history. What closes it: The design must assess prior injury and restraint history, ongoing IL-10 production, and the timing of contact shortening relative to improved killing. A result limited to final killing counts would not establish that accumulated suppression has been distinguished from the proposed contact mechanism.
What would make this wrong. With infection control independently verified and PD-1 stimulation shown to work, failure to improve either infected-target or cancerous-target killing would reject the proposal as specified. Persistence of the benefit when a killing cell is confined with a single target would also reject its claimed dependence on escaping harmless contacts. The supplied material specifies neither the effective bounded range of stimulation nor a numerical improvement criterion, so these cannot be supplied here.
What it would change. If the mechanism held, restoring protection in the affected subset of older adults would require attention to how killing cells distribute their time among encounters, because stronger restraint could improve total protective killing. Releasing restraint after infection control would then depend on the state of those contacts as well as tissue repair. Even successful results in cultures made from older donors would establish only two selected killing functions outside the body, not durable restoration of innate and adaptive immunity, preservation of memory and self-tolerance, or long-term control of latent infections.
Sources read · 8
Glycoengineering-based anti-PD-1-iRGD peptide conjugate boosts antitumor efficacy through T cell engagement. · Cell reports. Medicine · 2024
“Flow cytometry exhibited significantly increased cell engagement between OT-I cells and tumor cells in the αPD-1-(iRGD) 2 group.”
Does not settle: This source does not test increasing PD-1-mediated restraint, contact termination, older adults, infected targets, repairing uninfected bystanders, surveillance encounters per hour, collateral injury, or whether persistent effector-bystander conjugates drive surveillance failure.
Transforming acidic coiled-coil-containing protein 3-mediated lipid metabolism reprogramming impairs CD8+ T-cell cytotoxicity in hepatocellular carcinoma. · Signal transduction and targeted therapy · 2025
“The potential of combination therapy with PD-1 blockade and GalNAc–siTACC3 was further validated in preclinical murine models”
Does not settle: It does not assess cytotoxic-cell contact duration or termination, uninfected repairing bystanders, older adults, surveillance encounters per hour, collateral injury, or whether increasing PD-1 signaling restores killing.
Tumour-retained activated CCR7+ dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity. · Nature communications · 2024
“The prolonged tumour dwell-time of CCR7 + DCs, which maintain high levels of PD-1 ligand expression but downregulate expression of genes enabling effector function, suggests that these cellular interactions are potentially deleterious.”
Does not settle: The source does not establish prolonged nonproductive cytotoxic-cell contacts with repairing uninfected cells, PD-1 as a necessary contact-termination signal, or that increasing checkpoint signalling restores antiviral or abnormal-cell surveillance in older adults.
Potentiating cancer immunotherapies with modular albumin-hitchhiking nanobody-STING agonist conjugates. · Nature biomedical engineering · 2025
“High metastatic tumour burden was evident in mice receiving anti-PD-L1 ICB alone but significantly reduced in mice receiving nAlb–diABZI and nearly eliminated in mice receiving AP–diABZI.”
Does not settle: This mouse melanoma study does not examine older adults, PD-1-mediated contact termination, cytotoxic-cell contacts with repairing uninfected cells, surveillance encounters per hour, collateral injury, or whether increasing checkpoint signaling restores antiviral or abnormal-cell surveillance.
Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors. · JCI insight · 2021
“These data demonstrate that cell-bound PD-1 agonist ImmTAAI molecules potently inhibit CD8 + T cell cytokine secretion and confer protection from autoreactive CD8 + T cell–mediated cytotoxicity in vitro.”
Does not settle: This in vitro study does not examine older adults, postchallenge surveillance, persistent effector–bystander contacts, contact termination, surveillance encounters per hour, antiviral or malignant targets, or a bounded agonist range that restores protective killing.
SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity. · Nature · 2023
“Combinatorial treatment with glutamine enhanced the efficacy of anti-PD-1-mediated ICB therapy, with the majority (67%) of combination therapy-treated mice completely rejecting MC38 tumours and surviving”
Does not settle: This mouse tumour study does not test PD-1-mediated termination of cytotoxic-cell contacts, persistent effector–bystander conjugates, repairing uninfected cells, older adults, antiviral surveillance, or whether increasing PD-1 signalling restores killing.
TRIM28 drives immune evasion via PARP1 SUMOylation and NAD+ depletion in clear cell renal cell carcinoma. · Journal for immunotherapy of cancer · 2025
“Notably, the combination of Eltrombopag and PD-1 blockade resulted in a significantly greater reduction in tumor burden and a more substantial improvement in OS compared with either Eltrombopag or anti-PD-1 therapy alone”
Does not settle: This source does not examine older adults, repairing uninfected bystanders, cytotoxic-cell contact duration or termination, antiviral surveillance, collateral injury, or whether increasing PD-1 signaling within a bounded range restores surveillance.
Ferroptosis of tumour neutrophils causes immune suppression in cancer. · Nature · 2022
“In these tumor models, liproxstatn-1 enhanced the antitumor effect of ICB with PD-1 antibody ( ).”
Does not settle: This source does not establish PD-1-mediated contact termination, persistent cytotoxic-cell–bystander conjugates, older-adult postchallenge surveillance, tissue repair, collateral injury, or whether increasing checkpoint signaling restores surveillance.
The gap this hypothesis explains
Two established results predict opposite outcomes, and both cannot be right.
Does lifting immune restraint after infection restore protective detection only after repair, with earlier release harming tissue and delay prolonging suppression?
Original wording · exactly as the pipeline generated it
Does releasing postchallenge immune restraint after verified pathogen control restore surveillance only after tissue repair, with earlier release worsening injury and later release entrenching suppression?
What this question is asking
The question concerns when to lift the controls that limit immune activity after an infection has been brought under control. It asks whether release before, after, or long after tissue repair changes the ability to detect and respond to viruses and abnormal cells. It assumes that early release can worsen injury, while delayed release can make reduced immune activity persist. The proposed timing window must preserve protection against both threats without renewed injury or attacks on the body's own tissues. The broader concern is lasting recovery of immune function in people with age-related immune dysfunction, but the supplied sources do not establish that outcome.
- Immune restraint
- Controls that limit immune responses. The question treats their release as an intervention, but the supplied material does not specify one control or one way of releasing it.
- Immune suppression
- Reduced immune activity or responsiveness. Persistent suppression would mean that this reduction continues; the sources do not establish when it becomes entrenched or difficult to reverse.
- Immune surveillance
- The ability to detect and respond to threats, here viruses and abnormal cells. These are separate protective functions, so recovery of one would not establish recovery of both.
- Pathogen control and burden
- A pathogen is an infection-causing agent, and its burden is the amount present. Verified control means evidence that infection has been brought under control, but the supplied material does not define the required measurement or establish that control means complete elimination.
- Tissue repair
- Recovery of damaged body structures. Repair is a process rather than a single established endpoint here; no supplied criterion defines when enough has occurred for release.
- Regulatory T cells
- Immune cells that limit other immune responses and participate in tissue repair. Those functions can protect tissue, while S3 describes repair activity that also needs limits to prevent harmful scarring.
- Killer T cells
- Immune cells capable of attacking target cells. S7 examines their responses against microglia, rather than restoration of both surveillance functions after infection control.
- Microglia
- Immune cells resident in the brain and spinal cord. They are the targets examined in S7's laboratory model.
- Fibrosis
- Accumulation of scar tissue. In S3, it is the harmful consequence for which repair functions need limits.
- Chronic rejection
- Ongoing damage to a transplanted organ involving immune responses. S3 concerns this transplant outcome, which differs from recovery after infection.
- Self-tolerance, autoreactivity, and autoimmunity
- Self-tolerance is the immune system's restraint toward the body's own tissues; autoreactivity is immune activity directed against them. Autoimmunity involves such activity causing harmful responses, as reported after regulatory T cell depletion in S9.
- Cell depletion
- An intervention that removes or substantially reduces a cell population. Removing regulatory T cells is not necessarily equivalent to selectively releasing one of their restraining functions.
- Age-related immune dysfunction
- Changes associated with aging that impair immune function. This is the intended human context of the broader question, not a population in which the supplied evidence establishes the proposed window.
- Immune memory
- The retained ability to respond to a previously encountered threat. The broader question requires that recovery preserve this protection.
- Latent infections
- Infections that remain in the body in an inactive or relatively quiet state and can become active again. Maintaining their control is another required outcome that the supplied evidence does not establish.
Postchallenge immune restraint protects tissue repair, but prolonged restraint entrenches suppression, creating a burden-and-repair-defined release window that restores antiviral and abnormal-cell surveillance without rebound injury or autoreactivity.
The assumption concerns immune controls that remain active after infection and the tissues recovering from it. It claims that the amount of infection remaining and the progress of repair together determine when those controls become more harmful than helpful. If true, this would make those two measurements a basis for identifying when protective responses can resume safely.
S7 supports a narrower claim that regulatory T cells limit tissue damage during viral infection. S3 describes repair functions in a heart-transplant model as likely beneficial early but needing limits to prevent scarring that causes chronic rejection. Neither establishes that prolonged restraint entrenches suppression, that completed repair is necessary for restored surveillance, or that remaining infection and repair define a safe release window. The supplied sources do not establish those stronger assertions; this does not show that they are false.S7S3
The same question asked without the part nothing read establishes:
- After verified infection control, how does the timing of lifting immune restraint relative to tissue repair affect virus detection, abnormal-cell detection, tissue injury, and attacks on the body's own tissues?
- After verified infection control, does lifting immune restraint restore responses to viruses and abnormal cells without increasing tissue injury?
- A repair-linked release window exists Under the proposed mechanism, restraint would protect recovering tissue until repair has progressed sufficiently, after which release would restore responses to viruses and abnormal cells. Earlier release would renew injury, while substantially delayed release would leave protective responses persistently reduced.
- Release before completed repair is safe Protective responses could return while repair is still underway without increasing injury or attacks on the body's own tissues. Completed repair would therefore not be a necessary condition for release, and waiting for it could unnecessarily prolong reduced protection.
- Release does not safely restore both responses Lifting restraint could fail to recover one or both protective responses, or recovery could come with renewed injury or attacks on the body's own tissues. Timing release around repair would then be insufficient to deliver the combined outcome the question requires.
- Later release remains effective If delayed release still restores protective responses safely, prolonged restraint would not necessarily make suppression persistent. The proposed late boundary of the release window would therefore not follow.
Immune restraint limits responses that can damage tissue; S7 describes tissue damage following removal of regulatory T cells during viral infection. If lifting restraint restores protective detection, its benefit would depend on whether damaging responses also resume; that is the question's proposed tradeoff, not an established result. S3 adds a different concern: repair functions described as likely beneficial early can also contribute to harmful scarring if insufficiently limited. Treating these observations as proof of a release window could therefore mistake evidence about tissue protection and repair for evidence that both forms of protective detection recover safely.
RL-1–2 mechanisms predict both repair protection and prolonged suppression; antiviral and abnormal-cell recognition impose different requirements.
Restraint relaxes within recovery windows while surveillance respects separate protective floors and self-tolerance remains within prespecified limits.
Identify whether a burden-and-repair-defined release window restores both surveillance axes without rebound injury or autoreactivity.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
In a subset of older adults, postchallenge surveillance failure is driven by prolonged, nonproductive cytotoxic-cell contacts with uninfected repairing cells. PD-1-mediated restraint provides a necessary contact-termination signal: it interrupts weak, nonlethal encounters while permitting sufficiently strong encounters with infected or malignant targets to complete killing. Releasing restraint increases activation per encounter but immobilizes effectors among repairing bystanders, reducing successful surveillance encounters per hour and increasing collateral injury. The heretical claim is that increasing, rather than releasing, this checkpoint signal within a bounded range restores both antiviral and abnormal-cell surveillance before tissue repair is complete. The maladaptive state resides in persistent effector–bystander conjugates, not depleted cells, altered target susceptibility, or insufficient tissue entry.
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
After independently verified control of the initiating pathogen, introduce separately identifiable virus-bearing, malignant, and uninfected autologous targets into aged-donor immune–epithelial cultures. Compare reversible PD-1 agonism, blockade, and controls at matched repair stages. Agonism should shorten nonproductive bystander-contact duration, increase distinct pathological targets killed per effector-hour on BOTH surveillance axes, and reduce uninfected-cell injury despite lowering proximal activation signals. Its benefit should disappear when single-effector/single-target confinement removes the need to terminate bystander encounters. Blockade should show the opposite spatial dependence. Failure to improve either surveillance axis, or persistence of the benefit under single-target confinement, rejects this proposed mechanism.
States a measurable outcome; comparing rivals needs more conditions. The prediction specifies directional changes in observable outcomes, a condition eliminating the benefit, and explicit rejection criteria. No rival prediction is supplied. A paper already fetched for this hypothesis bears on it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
Live imaging, target barcoding, apoptosis reporters, and single-cell microwells permit direct separation of encounter frequency, contact termination, and killing probability. Use Fc-silent reagents with demonstrated agonism and measured receptor engagement. This is an ex vivo mechanistic test; recovery of two selected killing functions cannot establish decade-long protection or generalize automatically to NK-dependent tumor surveillance.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
After independently verified control of the initiating pathogen, introduce separately identifiable virus-bearing, malignant, and uninfected autologous targets into aged-donor immune–epithelial cultures. Compare reversible PD-1 agonism, blockade, and controls at matched repair stages. Agonism should shorten nonproductive bystander-contact duration, increase distinct pathological targets killed per effector-hour on BOTH surveillance axes, and reduce uninfected-cell injury despite lowering proximal activation signals. Its benefit should disappear when single-effector/single-target confinement removes the need to terminate bystander encounters. Blockade should show the opposite spatial dependence. Failure to improve either surveillance axis, or persistence of the benefit under single-target confinement, rejects this proposed mechanism.
- What would separate them
Accumulated immune restraint prolongs suppression after tissue repair predicts: Generate cultures with different durations of injury-driven restraint saturation, then match current repair, viable pathogen burden, immune-cell composition, extracellular IL-10, and measured suppressive activity. Cultures with longer saturation histories should retain greater nascent IL10 transcription or production capacity and develop a longer suppressive rebound after an identical brief IL-10R blockade and complete reagent washout. Temporarily stopping new IL-10 production while matching extracellular IL-10 exposure should discharge this backlog and prevent rebound without changing the repair stage at release. Failure of measured production state to predict held-out recovery trajectories, or identical recovery despite different verified accumulated production states, rejects the windup model.
Why this is not the mainstream account
The engine is asked to say what its hypothesis would overturn and what would surprise a specialist. This is its answer.
Fife et al. demonstrated that PD-1–PD-L1 interactions interrupt the TCR-induced stop signal: [Nature Immunology, 2009](https://pubmed.ncbi.nlm.nih.gov/19783989/). Separately, live human tumor imaging associated an exhausted T-cell state with greater motility: [Active surveillance characterizes human intratumoral T cell exhaustion](https://pubmed.ncbi.nlm.nih.gov/34292884/). These observations support the contact-dynamics premise, but neither demonstrates improved killing from agonism.
Postinfectious checkpoint immunology and cancer immunotherapy: the textbook chapter 'T-cell effector mechanisms and inhibitory checkpoint regulation' would require a model in which stronger inhibitory signaling can increase completed protective killing through contact termination, even during incomplete repair.
A checkpoint agonist simultaneously increases completed antiviral and malignant-target kills while reducing autologous injury, and this advantage vanishes when competing bystander contacts are experimentally removed.
The established PD-1 motility effect is not itself heretical. The proposed revision is the stronger causal claim that bounded PD-1 agonism restores both antiviral and malignant-target killing during aged convalescence, while blockade worsens both through bystander arrest. Targeted searches did not identify a review advocating that complete claim. This is provisional novelty evidence, not proof that no such publication exists.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
This hypothesis states no figure and cites no study, so there is nothing here to trace.
What it would take to refute it. 6 paper(s) already retrieved for this hypothesis carry its prediction’s terms. Reading them comes before running anything. Already retrieved: 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.; 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.; Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association..
7 papers retrieved around this hypothesis
- Beyond Glucose-Rethinking Prediabetes for Precision Prevention.PMID 40932411 · full_text · 68,453 characters stored
- 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.PMID 39866113 · full_text · 3,381,282 characters stored
- 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.PMID 38264914 · full_text · 3,103,128 characters stored
- Respiratory Vaccination with Hemagglutinin Nanoliposomes Protects Mice from Homologous and Heterologous Strains of Influenza Virus.PMID 36106872 · full_text · 3,942 characters stored
- Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association.PMID 36695182 · full_text · 2,880,681 characters stored
- Distinct early cellular kinetics in participants protected against colonization upon Bordetella pertussis challenge.PMID 36649086 · full_text · 77,681 characters stored
- 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.PMID 39866113 · full_text · 3,381,303 characters stored
0 citation handles extracted; 1 Europe PMC search run; 8 records examined; 6 sources stored for enrichment, 6 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.